deltatrials
Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT04075110

Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus

Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled Trial

Sponsor: Sadat City University

Conditions Obesity; Endocrine; Diabetes Type 2
Interventions Montelukast 10mg Placebo
Updated 16 times since 2019 Last updated: Apr 10, 2023 Started: Jul 1, 2019 Primary completion: Jun 1, 2022 Completion: Apr 10, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Obesity; Endocrine; Diabetes Type 2 and is currently completed. Sadat City University leads this study, which shows 16 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2020 · 13 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Feb 2022 · 3 months · monthly snapshot~Feb 2022 – ~Jul 2022 · 5 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~May 2023 · 3 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed EARLY_PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed EARLY_PHASE1

  3. May 2023 — Jul 2024 [monthly]

    Completed EARLY_PHASE1

    Status: Active Not Recruiting → Completed

  4. Feb 2023 — May 2023 [monthly]

    Active Not Recruiting EARLY_PHASE1

  5. Nov 2022 — Feb 2023 [monthly]

    Active Not Recruiting EARLY_PHASE1

▶ Show 11 earlier versions

  1. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting EARLY_PHASE1

  2. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Feb 2022 — Jul 2022 [monthly]

    Recruiting EARLY_PHASE1

    Status: Active Not Recruiting → Recruiting

  4. Nov 2021 — Feb 2022 [monthly]

    Active Not Recruiting EARLY_PHASE1

  5. Oct 2021 — Nov 2021 [monthly]

    Active Not Recruiting EARLY_PHASE1

  6. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting EARLY_PHASE1

  7. Feb 2021 — Sep 2021 [monthly]

    Active Not Recruiting EARLY_PHASE1

  8. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting EARLY_PHASE1

  9. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Status: Recruiting → Active Not Recruiting

  10. Oct 2019 — Nov 2020 [monthly]

    Recruiting EARLY_PHASE1

  11. Sep 2019 — Oct 2019 [monthly]

    Recruiting EARLY_PHASE1

    First recorded

Jul 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sadat City University
Data source: Sadat City University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations